{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216739","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2026-05-11T20:05:19+00:00","discovered_at":"2026-05-11T20:07:00.351027+00:00","generated_at":"2026-05-11T22:51:48.143073+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Erasca posts Q1 net loss of $183.4M; cash $408.5M; advances ERAS-0015 with robust early data","bullets":["Net loss of $183.4M ($0.60 per share) vs $31.0M loss a year ago; includes $150M in-process R&D charge for license expansion.","Cash and securities of $408.5M as of Mar 31, 2026, expected to fund ops into H2 2028; completed $258.8M public offering in Jan.","ERAS-0015 dose escalation showed robust responses in KRAS G12X NSCLC and PDAC with favorable safety; no TRAE discontinuations.","Monotherapy expansion and combo with panitumumab initiated ahead of schedule; data expected H1 2027.","Entered CTCSA with Merck for ERAS-0015 + KEYTRUDA combo; also with Tango for PRMT5 inhibitor combo."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216739","json":"https://secwatch.observer/filing/0001193125-26-216739.json","markdown":"https://secwatch.observer/filing/0001193125-26-216739.md","text":"https://secwatch.observer/filing/0001193125-26-216739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526216739/0001193125-26-216739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526216739/eras-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:51:48.143073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7047359bc3dc4de2656e0e6080fc48ef2dc7d861","claim":"Erasca, Inc. reported financial results for the fiscal quarter ended March 31, 2026.","evidence_excerpt":"On May 11, 2026, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526216739/0001193125-26-216739-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}